logo

Eiger Biopharmaceuticals Inc. (EIGR)



Trade EIGR now with
  Date
  Headline
8/13/2018 8:07:13 AM Eiger BioPharma Announces Completion Of Enrollment In Phase 2 PREVENT Study Of Avexitide
8/13/2018 7:27:30 AM Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) FY19 Estimate To -2.60 From -2.78
8/13/2018 7:27:13 AM Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) Q4 19 Estimate To -0.69 From -0.73
8/13/2018 7:26:51 AM Wedbush Is Raising Eiger BioPharmaceuticals Inc. (EIGR) Q3 19 Estimate To -0.66 From -0.71
8/13/2018 7:26:33 AM Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) Q2 19 Estimate To -0.64 From -0.68
8/13/2018 7:26:22 AM Wedbush Is Raising Eiger BioPharmaceuticals Inc. (EIGR) Q1 19 Estimate To -0.61 From -0.66
8/13/2018 7:26:09 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) FY18 Estimate To -2.71 From -2.65
8/13/2018 7:25:46 AM Wedbush Reiterates Eiger BioPharmaceuticals Inc. (EIGR) At Outperform With $53 Price Target
8/10/2018 8:05:06 AM Eiger BioPharma Q2 Net Loss $9.9 Mln Or $0.82/shr Vs. Net Loss Of $11.1 Mln Or $1.33/shr Prior Year
6/4/2018 8:16:53 AM Eiger BioPharma Announces HDV Phase 2 Program Oral Presentation For Planned HDV Phase 3 D-LIVR Study
5/17/2018 7:21:11 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) FY19 Estimate To -2.78 From -2.42
5/17/2018 7:20:59 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q4 19 Estimate To -0.73 From -0.64
5/17/2018 7:20:46 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q3 19 Estimate To -0.71 From -0.62
5/17/2018 7:20:33 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q2 19 Estimate To -0.68 From -0.59
5/17/2018 7:20:18 AM Wedbush Is Lowering Eiger BioPharmaceuticals Inc. (EIGR) Q1 19 Estimate To -0.66 From -0.57
5/17/2018 7:20:04 AM Wedbush Is Lowering Eiger BioPharmaceuticals Inc. (EIGR) FY18 Estimate To -2.65 From -2.32
5/17/2018 7:19:49 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q4 18 Estimate To -0.53 From -0.46
5/17/2018 7:19:37 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q3 18 Estimate To -0.60 From -0.53